Triptorelin
- Generic Name
- Triptorelin
- Brand Names
- Decapeptyl, Trelstar, Triptodur
- Drug Type
- Small Molecule
- Chemical Formula
- C64H82N18O13
- CAS Number
- 57773-63-4
- Unique Ingredient Identifier
- 9081Y98W2V
- Background
Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.
- Indication
Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
- Associated Therapies
- Controlled ovarian hyperstimulation therapy
Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children
- Conditions
- Central Precocious Puberty
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2007-02-22
- Lead Sponsor
- University of Pisa
- Target Recruit Count
- 100
- Registration Number
- NCT00438217
- Locations
- 🇮🇹
Center of Pediatric endocrinology, Department of Pediatrics, University of Pisa, Pisa, Italy
Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 100
- Registration Number
- NCT00415246
- Locations
- 🇧🇪
ULB Erasme, Bruxelles, Belgium
🇫🇷Hôpital Claude Huriez, Lille, France
🇫🇷CHU Hôpital Salvator, Marseille, France
HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2006-12-15
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 1294
- Registration Number
- NCT00412022
- Locations
- 🇮🇹
Istituto Nazionale per la ricerca Sul Cancro, Genova, Italy
🇮🇹Ospedale Santa Chiara, Trento, Italy
🇮🇹Ospedale Unico della Versilia, Lucca, Italy
Investigation of Early Hormonotherapy Efficacy of Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2006-09-13
- Lead Sponsor
- Kaunas University of Medicine
- Target Recruit Count
- 61
- Registration Number
- NCT00375687
- Locations
- 🇱🇹
Urology dep. of Kaunas University of Medicine, Kaunas, Lithuania
Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery
- Conditions
- Breast Cancer
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Gruppo Italiano Mammella (GIM)
- Target Recruit Count
- 280
- Registration Number
- NCT00311636
- Locations
- 🇮🇹
Ospedale Civile, Castelfranco - TV, Italy
🇮🇹Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
🇮🇹Ospedale Sant Anna, Como, Italy
Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer
- Conditions
- Estrogen Receptor-positive Breast CancerStage IIIA Breast CancerHER2-negative Breast CancerProgesterone Receptor-positive Breast CancerStage I Breast CancerStage II Breast Cancer
- Interventions
- Procedure: therapeutic conventional surgeryRadiation: radiation therapyOther: laboratory biomarker analysis
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 28
- Registration Number
- NCT00194792
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Triptorelin for Ovary Protection in Childhood Onset Lupus
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Other: placebo
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 31
- Registration Number
- NCT00124514
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States
Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 378
- Registration Number
- NCT00104741
- Locations
- 🇫🇷
Centre Hospital Regional Universitaire de Limoges, Limoges, France
🇫🇷Centre Hospitalier Universitaire Henri Mondor, Creteil, France
🇫🇷Clinique De Rochebelle, Ales, France
Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer
- First Posted Date
- 2004-09-08
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 49
- Registration Number
- NCT00090844
- Locations
- 🇺🇸
MBCCOP - JHS Hospital of Cook County, Chicago, Illinois, United States
🇺🇸MBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia, United States
🇺🇸CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States
Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-12-09
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- St. Luke's Hospital, Ireland
- Target Recruit Count
- 276
- Registration Number
- NCT00003734
- Locations
- 🇮🇪
Cork University Hospital, Cork, Ireland
🇮🇪Letterkenny Hospital, Donnegal, Ireland
🇮🇪St. Vincent's Hospital, Dublin, Ireland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.